A Mini Review: Mucormycosis in Coronavirus Disease-19, Host-Iron Assimilation, and Probiotics as Novel Therapy
Ankit Bhardwaj1★, Vandana Roy2, Indu Priyadarshini1★ Corresponding author
- 1Department of Pharmacology, ABVIMS and Dr. RML Hospital, New Delhi, India.
- 2Department of Pharmacology, MAMC and LNJP Hospital, New Delhi, India.
CORRESPONDENCE
Ankit Bhardwaj
Department of Pharmacology, ABVIMS and Dr. RML Hospital, Baba Kharak Singh Marg, Near Gurudwara Bangla Sahib, Connaught Place, New Delhi ‑ 110 001, India.
Received: 23-05-2021; Accepted: 04-08-2021.
Volume 12, Issue 3 · pp. 120–124 · PUBLISHED 25 November 2021 · DOI: 10.4103/jpp.jpp_58_21
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Mucormycosis is an acute fungal infection with 90% of cases in the form of rhino-orbito-cerebellar. It is an aggressive and life-threatening fungal infection causing 50% mortality in people with coronavirus disease 2019 (COVID‑19). In COVID‑infected patients due to, diabetic ketoacidosis, epithelial damage, ciliary dysfunction, dysfunctional phagocytic mechanism, and immunosuppression, there is impaired chemotaxis and defective intracellular killing leads to fungal spores to invade, germinate and penetrate in surrounding tissues. The use of broad‑spectrum antibiotics disrupts the normal microbiomes and increases the probability of growth of Rhizopus spp. Commercially available probiotics such as Lactobacillus, Bifidobacterium, Enterococcus, Streptococcus, and Saccharomyces when administered in adequate quantities form siderophores which induces iron stress in fungus and inhibits spore germination.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Bhardwaj, A., Roy, V., & Priyadarshini, I. (2021). A Mini Review: Mucormycosis in Coronavirus Disease-19, Host-Iron Assimilation, and Probiotics as Novel Therapy. Journal of Pharmacology and Pharmacotherapeutics, 12(3), 120–124. https://doi.org/10.4103/jpp.jpp_58_21